Methods and devices for the treatment of respiratory disease
Patent Information
- Application Number
- MYPI2026002725
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-11-08
- Filing Date
- 2024-11-08
- Publication Date
- 2025-05-08
Abstract
Description
METHODS AND DEVICES FOR THE TREATMENT OF RESPIRATORY DISEASESCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority of U.S. Provisional Patent Application No. 63 / 547,779 filed November 8, 2024, which is incorporated herein by reference in is entirety.FIELD OF THE INVENTION
[0002] This disclosure relates to the delivery of therapeutic agents to the respiratory system via a droplet delivery device, and more specifically via an electronic droplet delivery device.BACKGROUND OF THE INVENTION
[0003] The use of aerosol generating devices for the delivery of substances to the respiratory system is an area of large interest. A major challenge is providing a device that delivers an accurate, consistent, and verifiable dose, with a droplet size that is suitable for successful delivery of substances to the targeted passageways.
[0004] Aerosol verification, delivery and inhalation of the correct amount at the desired times is important. A need exists to ensure that users correctly use aerosol devices, and that they administer the proper amount at desired time. Problems emerge when users misuse or incorrectly delivery’ substances to the respiratory’ system.
[0005] Droplets with diameters between 0.5 pm and 7 pm will effectively deposit substances in the lung. Droplets larger than this range of sizes are mostly deposited in the mouth and upper respiratory’ tract, and droplets smaller than this range mostly fail to settle and are exhaled. Efficient alveolar deposition can generally be achieved with droplets having diameters in the 1 to 5 pm range (Hinds page 142 from Lippmann 1977). Compositions intended for quick systemic uptake via pulmonary' delivery typically target the alveolar region where the blood-gas interface provides rapid transport of substances from the alveoli to the bloodstream.
[0006] There is a need for improved methods and devices for delivering droplets to the respiratory systems via a droplet delivery device.DETAILED DESCRIPTION
[0007] Certain aspects of the disclosure relate to a method of delivering one or more therapeutic agents to one or more portions of the respiratory system with an electronic breath actuated aerosol delivery devices that is particularly configured for the delivery of small droplets to the respiratory system (referred herein as a droplet delivery device). Droplet delivery devices and methods of delivering droplets / agents that may be used with the methods described herein include, but are not limited to, those described in PCT / US2017 / 030913 (WO2017 / 192767), PCT / 2017 / 030917 (WO2017 / 192771), PCT / 2017 / 030919(WO2017 / 192773), PCT / US2017 / 030921 (WO2017 / 192774), PCT / US2017 / 030929 (WO2017 / 192782), PCT / 2017 / 030925 (WO2017 / 192778), PCT / US2018 / 054417 (WO2019 / 071008), PCT / US2018 / 056300 (WO 2019 / 079461, PCT / 2018 / 059874(WO2019 / 094628), PCT / 2019 / 012691 (WO2019 / 136437), PCT / US2019 / 25321 (WO2019 / 195239), PCT / 2019 / 054042 (W02020 / 072478). PCT / US2020 / 014785 (W02020 / 154497), PCT / US2020 / 032383 (WO2020 / 227717), PCT / US2020 / 040132(W02020 / 264501), PCT / US2022 / 035492, PCT / US2022 / 026176, PCT / US2022 / 034552, US Provisional Patent Application No. 63 / 256,245, US Provisional Patent Application No. 63 / 318.202, US Provisional Patent Application No. 63 / 323,770, US Provisional Patent Application No. 63 / 346,794, US Provisional Patent Application No. 63 / 337,885, US Provisional Patent Application No. 63 / 390,170, US Provisional Patent Application No. 63 / 390,209, and US Provisional Patent Application No. 63 / 390,228, the disclosures of which are each incorporated herein by reference in their entirety for all purposes.
[0008] In other aspects, the disclosure provides compositions for delivery of small droplets comprising one or more therapeutic agents to one or more portions of the respiratory system via a droplet delivery device. The compositions may be designed to stabilize the one or more therapeutic agents and allow for effective delivery of the therapeutic agent(s) via a small droplets as disclosed herein. The compositions may be specifically designed to work with a droplet delivery device as described and / or referenced herein. The compositions may be designed to allow for the formation of droplets having the desired diameter in a droplet delivery device. The droplet delivery device may be one disclosed and / or referenced herein. The composition may be a pharmaceutical composition.
[0009] In other aspects, the disclosure provides methods for delivery of small droplets comprising one or more therapeutic agents to one or more portions of the respiratory system via a droplet delivery' device that is particularly configured for the delivery' such small droplets.The size of the droplets can be tailored depending on the one or more therapeutic agents and / or the portion(s) of the respiratory’ system that the one or more therapeutic agents are to be delivered to. For example, droplets of about 10 pm or higher may be used to target the upper airway (e.g., throat). Droplets of about 4.5 to about 10 pm may be used to target the medium airway. Droplets of about 4.5 pm may be used to target the low airway (e.g., aveoli).
[0010] As discussed above, effective delivery of droplets deep into the lung airways require droplets that are less than about 5-6 microns (pm) in diameter, specifically droplets with mass mean aerodynamic diameters (MMAD) that are less than about 5 microns (pm). However, for certain agents and uses, droplets about 1 pm or smaller for quick adsorption in the deep lung may be desirable, e.g., it may be desired to utilize droplets less than 4 pm, less than 2 pm, and less than 1 pm for the delivery’ of therapeutic agents and related substances to the deep lungs.
[0011] In other aspects of the disclosure, methods for generating an ejected stream of small droplets comprising one or more therapeutic agents for delivery to the respiratory system of user using the droplet delivery’ devices of the disclosure are provided. In certain embodiments, the ejected stream of droplets is generated in a controllable and defined droplet size range. By way of example, the droplet size range includes at least about 50%, at least about 60%, at least about 70%, at least about 85%, at least about 90%, between about 50% and about 90%, between about 60% and about 90%, between about 70% and about 90%, etc., of the ejected droplets are in the respirable range of below about 4 pm, below about 3 pm, below about 2.5 pm, below about 2 pm, between about 0.7 pm and about 4 pm, between about 0.7 pm and about 3 pm, between about 0.7 pm and about 2.5 pm, between about 0.7 pm and about 2.0 pm, between about 0.7 pm and about 1.5 pm, between about 0.7 pm and about 1.0 pm, etc.
[0012] In other embodiments, the ejected stream of droplets comprising one or more therapeutic agents may have one or more diameters, such that droplets having multiple diameters are generated so as to target multiple regions in the airways (mouth, tongue, throat, upper airways, lower airways, deep lung, etc.) By way of example, droplet diameters may range from about 0.7 pm to about 200 pm, about 0.7 pm to about 100 pm, about 0.7 pm to about 60 pm, about 0.7 pm to about 40 pm, about 0.7 pm to about 20 pm. about 0.7 pm to about 5 pm, about 0.7 pm to about 4.7 pm, about 0.7 pm to about 4 pm, about 0.7 pm to about 3.0 pm, about 0.7 pm to about 2.5 pm, about 0.7 pm and about 2.0 pm, about 0.7 pm and about 1.5 pm, about 0.7 pm and about 1.0 pm, , about 5 pm to about 20 pm, about 5 pm to about 10 pm, and combinations thereof. In particular embodiments, at least a fraction of the droplets have diameters in the respirable range, while other droplets may have diameters in other sizesso as to target non-respirable locations (e.g.. larger than about 5 gm). Illustrative ejected droplet streams in this regard might have 50% - 70% of droplets in the respirable range (less than about 5 pm), and 30% -50% outside of the respirable range (about 5 pm - about 10 pm, about 5 pm - about 20 pm, etc.)
[0013] Effective delivery of droplets deep into the lung airways require droplets that are less than about 5-6 microns (pm) in diameter, specifically droplets with mass mean aerodynamic diameters (MMAD) that are less than about 5 microns (pm). The mass mean aerodynamic diameter is defined as the diameter at which 50% of the droplets by mass are larger and 50% are smaller. In certain aspects of the disclosure, in order to deposit in the alveolar airways, droplets in this size range must have momentum that is sufficiently high to permit ejection out of the device, but sufficiently low to overcome deposition onto the tongue (soft palate) or pharynx.
[0014] In other aspects of the disclosure, methods for generating an ejected stream of droplets comprising one or more therapeutic agents for delivery to the respiratory' system of user using the droplet delivery devices of the disclosure are provided. In certain embodiments, the ejected stream of droplets is generated in a controllable and defined droplet size range. By way of example, the droplet size range includes at least about 50%, at least about 60%, at least about 70%, at least about 85%, at least about 90%, between about 50% and about 90%, between about 60% and about 90%, between about 70% and about 90%, etc., of the ejected droplets are in the respirable range of below about 5 pm.
[0015] In other embodiments, the ejected stream of droplets comprising one or more therapeutic agents may have one or more diameters, such that droplets having multiple diameters are generated so as to target multiple regions in the airways (mouth, tongue, throat, upper airways, lower airways, deep lung, etc.) By way of example, droplet diameters may range from about 1 pm to about 200 pm, about 2 pm to about 100 pm, about 2 pm to about 60 pm, about 2 pm to about 40 pm, about 2 pm to about 20 pm, about 1 pm to about 5 pm, about 1 pm to about 4.7 pm, about 1 pm to about 4 pm, about 10 pm to about 40 pm, about 10 pm to about 20 pm, about 5 pm to about 10 pm, and combinations thereof. In particular embodiments, at least a fraction of the droplets have diameters in the respirable range, while other droplets may have diameters in other sizes so as to target non-respirable locations (e.g., larger than 5 pm). Illustrative ejected droplet streams in this regard might have 50% - 70% of droplets in the respirable range (less than about 5 pm), and 30% -50% outside of the respirable range (about 5 pm - about 10 pm. about 5 pm - about 20 pm, etc.). By way of anon-limiting example, w hen droplets of about 2 pm are used, about 70-80% of the respirable fraction reachthe alveoli. When droplets of about 3 pm are used, about 50-60% of the respirable fraction reach the alveoli. When droplets are less than about 2 pm, then the respirable fraction is 80- 90%.
[0016] In some embodiments, the methods involve the droplet device delivery the one or more active agents based on the volume of air that is inhaled by the subject. For example, to reach high airways - the one or more therapeutic agents are released by the droplet device after about 2L has been breathed in by the user (since aerosol is released later in inhaled breath it deposits higher in airway if droplet sizes are larger or constant). To reach low airways - the one or more therapeutic agents are released by the droplet device before 2L has been breathed in by the subject (since aerosol is released sooner it is inhaled deeper even if droplet sizes are larger or constant).
[0017] In certain embodiments, the methods of the disclosure may be used to deliver one or more therapeutic agents to treat various diseases, disorders, and conditions by delivering a therapeutic agent to the respiratory system of a subject. In this regard, in some embodiments, once delivered to the desired location(s) of the respiratory system, the one or more therapeutic agents may be localized (e.g., not systemic). In accordance with aspects of the disclosure, without intending to be limited by theory, providing direct delivery of one or more therapeutic agents to the target portion(s) of the respiratory system improve clinical outcomes. Inhaled delivery to the lung may permit high local concentrations that may not be safely attainable through a systemic route. Additionally, the incidence and severity of any associated non- respiratory adverse events may be lowered.
[0018] In other embodiments, once delivered to the desired location(s) of the respiratory system, the therapeutic agent may disperse so as to provide systemic delivery7to the body of the subject. In further embodiments, once delivered to the desired location(s) of the respiratory system, the therapeutic agent may exhibit both localized and systemic delivery.
[0019] The method may be used to deliver one or more therapeutic agents to the entire respiratory system, or it may be used to deliver one or more therapeutic agents to specific locations within the respiratory system. For example, the method may be used to delivery therapeutic agents to one or more portions of the upper airway (e.g.. nose, nasal passages, paranasal sinuses, the pharynx, and the portion of the larynx above the vocal cords). By way of another example, the methods may be used to deliver therapeutic agents to one or more portions of the lower respiratory system (e.g., trachea, bronchi and bronchioles, and the alveoli). In further embodiments, the methods may be used to deliver one or more therapeutic agents to the one or all portions of the lungs. For example, the methods may be used to deliverone or more therapeutic agents to one or more of the superior, middle, and / or inferior lobes. The methods may be used to deliver one or more therapeutic agents to one or more tissue types in the lungs (e.g., alveolar cells, bronchial epithelium, alveolar macrophages, endothelia cells, interstitial cells, etc.). By way of another, non-limiting example, the methods may be used to deliver one or more therapeutic agents the bronchial epithelium. The tissue types may be normal and / or abnormal (e g., diseased, precancerous, cancerous, virally infected, etc ). Again, localized delivery has the benefit of avoiding negative outcomes associated with systemic delivery of certain therapeutics (such as cancer treatments).
[0020] In some embodiments, the methods and droplet delivery devices of the disclosure may be used to treat or prevent diseases, disorders, and conditions. In certain embodiments, the methods and droplet delivery devices of the disclosure may be used to treat or prevent a cancerous or precancerous condition (e.g., precancerous lesions) or dysplasia. In other embodiments, the methods and droplet delivery devices of the disclosure may be used to treat or prevent bacterial infections, viral infections, and / or autoimmune disorders.
[0021] In some embodiments the methods and droplet delivery devices of the disclosure may be used to treat non-small cell lung cancer (NSCLC). pre-malignant lung lesions (such as bronchial dysplasia or ground glass opacities), pre-invasive lung lesions (hyperplasia, metaplasia, dysplasia, carcinoma-in-situ), squamous dysplasia, squamous cell carcinoma (SCC), and the like. Non-small cell lung cancer (NSCLC), which makes up the majority of lung cancers, is a disease in which malignant (cancer) cells form in the tissues of the lung. Non-small cell lung cancer is a group of lung cancer subtypes that behave similarly, such as adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, sarcomatoid carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as NSCLC because their treatment and prognoses (outlook) are often similar.
[0022] In other embodiments, the methods and droplet delivery device may be used for the delivery of one or more therapeutic agents including, but not limited to, small molecules, therapeutic peptides, therapeutic nucleic acids (e.g., DNA, RNA, ASOs, siRNA, etc ), proteins, antibodies, viruses, and other bioengineered molecules via the respiratory system. The one or more therapeutic agents can be selected by those of skill in the art based on the disease, disorder, and / or condition to be prevented or treated. Similarly, the specific location(s) in the respiratory system for delivery of the one or more therapeutic agents can be selected based be selected by those of skill in the art based on the disease, disorder, and / or condition to be prevented or treated.
[0023] In some embodiments, the one or more therapeutic agents may be delivered to one or more portion(s) of the respiratory system in combination with one or more other therapeutic agents that are delivered via another route (e.g., enteral, parenteral, topical, ocular, transdermal, intravenous, intramuscular, subcutaneous, intradermal, intrathecal, etc.). The other therapeutic agents may be delivered locally or systematically. In some embodiments, the one or more therapeutic agents may be delivered locally to one or more portion(s) of the respiratory system and the one or more other therapeutic agents that are delivered via another route are delivered systemically to the body of the subject.
[0024] In various aspects, the disclosure herein provides for a method of treating a cancerous or precancerous condition, including a precancerous lesion using one or more inhaled therapeutic agents. In certain embodiments, the method may comprise delivering one or more therapeutic agents for the treatment or prevention of precancerous lesions and / or dysplasia. In certain aspects, the one or more therapeutic agents may be administered to the respiratory system of a subject for treatment or prevention of a respiratory' cancer (primary', secondary, metastatic, etc.).
[0025] In certain embodiments, the cancer therapeutic may be comprised of the one or more therapeutic agents, a carrier, and other suitable pharmaceutically acceptable excipients. For instance, various carriers may include colloidal dispersions, microparticles, nanoparticles, polyketal microparticles and nanoparticles, liposomes (for example, see Gonzalez-Rothi. R.J., Schreier, H. Pulmonary Delivery of Liposome-Encapsulated Drugs in Asthma Therapy. Clin Immunother 4, 331-337 (1995)), https: / / doi.org / IO.1007 / BF03259296. disclosures of which are incorporated herein by reference in their entirety), polymer conjugates, protein or nucleic acid conjugates, dendrimers, nanostructured lipid carriers (NLC), nanospheres, and various combinations thereof. In some embodiments, the carrier may comprise a lipid nanoparticle.
[0026] In some embodiments, the therapeutic is encapsulated. Various types of encapsulation technology can be used such as lipid encapsulation. The encapsulation can increase resonance time. The encapsulation can allow for targeted delivery' of the therapeutic to the lungs without systematic uptake. Without being bound to any one theory, encapsulation minimizes systemic uptake for the therapeutic (such as a monoclonal antibody) and thus minimizes or prevents the triggering of a whole-body immune response. The type and thickness of encapsulation can be optimized to allow for effective delivery' of the therapeutic and / or minimizing / preventing a whole-body immune response.
[0027] In certain embodiments, the one or more of the cancer therapeutic may be selected from chemotherapeutic agents, immune checkpoint inhibitors, and other antibody and immune stimulating therapeutics, and various combinations thereof.
[0028] Exemplary chemotherapeutic agents include paclitaxel, doxorubicin, gemcitabine, 9-nitrocamptothecin, 5 -azacytidine, celecoxib, 5-fluorouracil, cisplatin, carboplatin, oxaliplatin, nedaplatin, picoplatin, and other known chemotherapy agents.
[0029] Exemplary immune checkpoint inhibitors include CTLA-4, LAG-3. PD-1, and / or PD-L1 inhibitors. In some embodiments, a PD-1 inhibitor such as pembrolizumab, nivolumab, cemiplimab, tislelizumab, etc. may be used. In some embodiments a PD-L1 inhibitors such as atezolizumab, avelumab, durvalumab, etc., may be used. In some embodiments a CTLA-4 inhibitors such as ipilimumab, etc., may be used. In some embodiments a LAG-3 inhibitor such as relatlimab, etc., may be used.
[0030] In other aspects, various targeted monoclonal antibodies may be used, e.g., Bevacizumab (anti-VEGF), Ramucirumab (anti-VEGFR2), Necitumumab (anti-EGFR), etc.
[0031] In some embodiments, the one or more therapeutic agents may be an antibody. The antibody may be a monoclonal antibody.
[0032] In some embodiments the antibody is an anti-PD-l / TGFbR2 mAb (LBL-015). In some embodiments the PD-l / TGFbR2 mAb is as described in U.S. Patent Application Publication No. 2021 / 0115142, disclosures of which are incorporated herein by reference in their entirety.
[0033] In some embodiments the antibody is an anti -PD-1 antibody. In some embodiments the anti-PD-1 antibody is as described in U.S. Patent No. 11,136,394, disclosures of which are incorporated herein by reference in their entirety. In some embodiments, the anti- PD-1 antibody is LBL-006.
[0034] In some embodiments the one or more therapeutic agents may be a recombinant fusion protein that is capable of binding to TGFp and capable of binding to PD-1. Said recombinant fusion protein can be an antibody or an antigen-binding fragment thereof. In some embodiments the recombinant fusion protein that is capable of binding to TGF(3 and capable of binding to PD-1 is as described in U.S. Patent Application Publication No. 2021 / 0115142, disclosures of which are incorporated herein by reference in their entirety.
[0035] Other immune stimulating therapeutics may include synthetic oligonucleotides that activate Toll-like receptors (TLRs), such as CpG oligonucleotides that activate TLR9.
[0036] In certain embodiments, combinations of one or more chemotherapeutic agents, e.g., platinum based chemotherapeutic agents or other chemotherapy agents together, to PD-1,e.g., nivolumab, and / or CTLA-4, ipilimumab, inhibitors may be used. For instance, cisplatin, docetaxel, or doxorubicin alone or in combination with one or more immune checkpoint inhibitors or other therapeutic agents may be used in connection with the methods of the disclosure.
[0037] By way of non-limiting example, therapeutic agents which may be delivered via the respiratory system for the treatment or prevention of respiratory cancer may include one or more of the following:• Chemotherapeutic Drugs: paclitaxel, doxorubicin, gemcitabine, 9-nitrocamptothecin, 5-azacytidine, celecoxib (+systemic docetaxel), 5 -fluorouracil, and / or cisplatin;• Immunotherapeutic Agents: IL-2, IL_2 (+ NK cell infusion), GM-CSF, CpG-ODN, and / or LPS;• Monoclonal Antibodies: cetuximab (anti-EGFR antibody), (cetuximab + avidinOX), relatlimab (anti-LAG-3 antibody), ipilimumab (anti-CTLA-4 antibody), dostarlimab (anti-PDCDl antibody). anti-PD-l / TGFbR2 mAb (LBL-015), anti-PD-1 antibody (LBL-006), pembrolizumab (anti-PD-1 antibody), nivolumab (anti-PD-1 antibody), cemiplimab (anti-PD-1 antibody), tislelizumab (anti-PDl antibody), atezolizumab (anti-PD-Ll antibody), durvalumab (anti-PD-Ll antibody), and / or avelumab (anti-PD- L1 antibody);• Check point inhibitors: PD-1 inhibitors (pembrolizumab, nivolumab, cemiplimab, tislelizumab, etc.), PD-L1 inhibitors (atezolizumab, avelumab, durvalumab, etc.), CTLA-4 inhibitors (ipilimumab, etc.), and / or LAG-3 inhibitors (relatlimab, etc.);• Genes: PEI-p53, PEI-IL-12, PEI-PTEN. BC-819, rAAV-ME-4E-BPl, DNA / Beclinl, PEI-p53 > 9 NC-DLPC, and / or adenoviral-type 5 with human ABCA10 transgene cisplatin; and / or• Antisense Oligonucleotides, siRNA. shRNA: Aktl siRNA, PEI-WT1 RNAi, small hairpin osetopontin, and / or MRP1 and BCL2 ASO.
[0038] In any of the aspects provided herein, the method may comprise delivering therapeutic nucleic acids to the subject. For example, the method may comprise delivering a virus or a viral vector comprising a nucleic acid that encodes for a gene, antisense oligonucleotide, siRNA, or shRNA. The therapeutic nucleic acids may comprise viral vectors (e.g, adenoviruses) designed to transfect and induce expression of a desired nucleic acid in cells that line the alveoli. In some cases, the therapeutic nucleic acid may comprise a dsRNA, a shRNA, an siRNA, and / or an oligonucleotide (e.g., an antisense oligonucleotide). The viralvector (virus) may be encapsulated in a lipid nanoparticle to facilitate entry into a cell in the lungs.
[0039] Certain benefits of the respiratory route for delivery of drugs and other medications include anon-invasive, needle-free delivery system that is suitable for delivery of a wide range of substances from small molecules to very large proteins, reduced level of metabolizing enzymes compared to the GI tract, and absorbed molecules do not undergo a first pass liver effect. (A. Tronde, et al., J Pharm Sci, 92 (2003) 1216-1233; A.L. Adjei, et al., Inhalation Delivery of Therapeutic Peptides and Proteins, M. Dekker, New York, 1997). Further, for local respiratory indications, medications that are administered orally or parenterally (IM, SC, IV, IP, etc.) are diluted through the body, while medications given directly into the lungs may provide concentrations at the target site (the lungs) that are about 100 times higher than the same parenteral dose. As such, in accordance with certain aspects of the disclosure, lower dosages may be administered to a subject via inhalation for local delivery' to the lungs, as compared to equivalently effective parenterally administered dosages. Such lower dosages may have the added benefit of reducing side effects of the active agent, e.g., due to reduced local and / or systemic exposure.
[0040] Another benefit of giving medication directly into the lungs is that systemic side effects can be minimized and / or prevented, e.g., as compared to oral, systemic, or parenteral administration. One of the systemic side effects that can be minimized / prevent is a wholebody immune response to the medication (therapeutic agent).
[0041] In certain aspects, in accordance with the present disclosure, it has been found that exemplary antibody compositions (hlgG) can be successfully delivered in a dose dependent manner to the lungs of a subject via inhalation using a device of the disclosure, and can be distributed in proximal and distal lung tissues, including alveoli, bronchioles, and trachea. In addition, it has been found that exemplary antibody compositions (hlgG) can be successfully delivered locally to the lungs via inhalation using a device of the disclosure in a manner that minimizes systemic uptake.
[0042] In this regard, in accordance with aspects of the disclosure, substantially larger dosages of active agent can be locally delivered to the lungs via inhalation in a manner that results in minimal systemic exposure to and uptake of the active agent. For instance, similar systemic plasma concentrations of an exemplary antibody are observed in subjects when dosed via inhalation at a dosage amount 250 times greater than when dosed via oral, systemic or parenteral route.
[0043] In another embodiment, methods for delivering safe, suitable, and repeatable dosages of a medicament to the respiratory system using the droplet delivery devices of the disclosure are provided. The methods deliver an ejected stream of droplets comprising the one or more therapeutic agents to the desired location within the respirator}' system of the subject, including the deep lungs and alveolar airways.
[0044] Suitable dosage and administration regimen may be determined based on the specific cancer therapeutic or combination of cancer therapeutic agents to be administered to the subject in need thereof. As discussed herein, the present methods and devices allow for delivery of high concentrations of active agent directly to the respiratory' system of a subject. Suitable dosages and dosing regimens may be determined based, at least in part, on lung clearance properties of the therapeutic agent and desired therapeutic concentrations of the therapeutic agent at the site of interest (e.g., tumor site, upper airways, lower airways, etc.). Many factors, including those described herein, can influence the desired dosage. Once the desired dosage is determined, and also if needed, desired frequency, such doses can be delivered. Frequency of dosing can vary’ by number of times, periodicity or both.
[0045] The term “therapeutically effective” amount refers to an amount of an active agent used to treat, ameliorate, prevent, or eliminate the identified condition (e.g., precancerous lesions or dysplasia), or to exhibit a detectable therapeutic or preventive effect. The effect can be detected by, for example, chemical markers, antigen levels, or time to a measurable event, such as morbidity or mortality. The precise effective amount for a subject will depend upon the subject’s body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration.
[0046] The disclosure provides compositions for delivery of small droplets comprising one or more therapeutic agents to one or more portions of the respiratory system via a droplet delivery device. The compositions may be designed to stabilize the one or more therapeutic agents. The compositions may be designed to reduce foaming of the composition when delivered via a droplet device. The compositions may be designed to optimize pH for stability' of the therapeutic agent(s) and / or optimize pH for delivery to the subject. The compositions may be designed to allow for effective delivery, deposition, absorption, etc. of the therapeutic agent(s) to a subject. The compositions may be designed to allow for effective delivery, deposition, absorption, etc. of the therapeutic agent(s) to a specific location of the respiratory system of the subject. The compositions may be designed to allow' for effective delivery' of the therapeutic agent(s) via a small droplets as disclosed herein. The compositions may be designed to be utilized in a method or droplet delivery device as described and / or referenced herein. Thecompositions may be designed to allow for the formation of droplets having the desired diameter in a droplet delivery device. The compositions may be designed to allow for stable storage of the therapeutic agent in a droplet delivery device. The droplet delivery device may be one disclosed and / or referenced herein. The composition may be a pharmaceutical composition.
[0047] In any of the methods provided herein, a droplet delivery device capable of aerosolizing a liquid and generating droplets having the preferred diameters as described below, may be used. Nonlimiting droplet delivery devices and method of delivering droplets / agents that may be used include those described in PCT / US2017 / 030913 (WO2017 / 192767), PCT / 2017 / 030917 (WO2017 / 192771), PCT / 2017 / 030919(WO2017 / 192773), PCT / US2017 / 030921 (WO2017 / 192774), PCT / US2017 / 030929 (WO2017 / 192782), PCT / 2017 / 030925 (WO2017 / 192778), PCT / US2018 / 054417 (WO2019 / 071008), PCT / US2018 / 056300 (WO 2019 / 079461, PCT / 2018 / 059874(WO2019 / 094628), PCT / 2019 / 012691 (WO2019 / 136437), PCT / US2019 / 25321 (WO2019 / 195239), PCT / 2019 / 054042 (W02020 / 072478). PCT / US2020 / 014785 (W02020 / 154497), PCT / US2020 / 032383 (WO2020 / 227717), PCT / US2020 / 040132(W02020 / 264501), PCT / US2022 / 035492, PCT / US 2022 / 026176, PCT / US2022 / 034552, US Provisional Patent Application No. 63 / 256,245, US Provisional Patent Application No. 63 / 318.202, US Provisional Patent Application No. 63 / 323,770, US Provisional Patent Application No. 63 / 346,794. US Provisional Patent Application No. 63 / 337.885, US Provisional Patent Application No. 63 / 390,170, US Provisional Patent Application No. 63 / 390,209, and US Provisional Patent Application No. 63 / 390,228, the disclosures of which are each incorporated herein by reference in their entirety.
[0048] While that disclosure covered the pneumatic delivery of small molecule therapeutics (e.g., chemotherapies) via the droplet delivery device, the disclosure herein provides for delivering nucleic acid-based therapeutics, and in particular - viral vectors or other viruses to alter gene expression in the lungs. This may be beneficial for treating or preventing the formation of precancerous lesions which may be caused by abnormal gene expression. For example, delivery of a viral vector (e.g., in a lipid nanoparticle) using a droplet delivery device such as described herein, to the alveoli may allow for precise control of gene expression in these cells. Detrimental genes may be downregulated (using e.g., shRNA or siRNA), expression of harmful, oncogenic proteins, may be reduced (e.g., using antisense oligonucleotides). Further, specific gene editing may occur to remove a mutation that leads to increased cancer risk.
[0049] Accordingly - provided herein are methods of delivering viral vectors to the respiratory system. In some aspects, the viral vectors are contained or delivered in a lipid nanoparticle.
[0050] All publications, patents, and patent applications cited in this specification are herein incorporated by reference as if each individual publication, patent, or patent application were specifically, and individually, indicated to be incorporated by reference.
[0051] While the invention has been described with reference to exemplary embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention will include all embodiments falling within the scope of the appended claims.EXAMPLES
[0052] The following examples are included to illustrate certain embodiments. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered to function well in the practice of the claimed methods, compositions and apparatus. However, those of skill in the art should, in light of the present disclosure, appreciate that changes can be made in some embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of embodiments of the inventions.Example 1.
[0053] In order to assess, validate, and optimize the use of therapeutic agents against cancer and pre-cancerous lesions in the lungs, the following methodology is employed.
[0054] Phase 1:• Step 1 : Preclinical testing o Investigational LBL-006 (human anti-PDl ) using live mice (see Example 2) o Test delivery method and chamber setup (see Example 2) o Test particle size diameter (MMAD)• Step 2: Refinement of testing on mice with LBL-006 o Validating the MMAD. chamber concentration, and lung deposition• Step 3: Testing of LBL-015 (human anti-PDl / TGFbetaR2) on mice (see Example 4) o Formulation development to retain protein stability o Perform testing based on result of previous studies
[0055] Phase 2: Tumorized mice studies• Use of mouse anti-PDl treatments o Monitoring tumor reduction, stabilization, or enlargement o Safety and efficacy• Use of mouse anti-TGFbetaR2 treatments o Monitoring tumor reduction, stabilization, or enlargement o Safety and efficacy• Use of a combination of mouse anti-PDl treatments and anti-TGFbetaR2 o Monitoring tumor reduction, stabilization, or enlargement o Safety and efficacy
[0056] Phase 3: Human tumorized mice studies using outside lab• Use of LBL-006• Use of LBL-015
[0057] Preclinical Trials:• Performing mouse deposition studies• Mouse tumor suppression studies using syngeneic mouse models with mouse checkpoint inhibitors• Human tumor suppression studies using humanized mice with checkpoint inhibitors
[0058] Preclinical Studies:• Maximize antibody deposition in mouse lung o Determining the media mass aerodynamic diameter (MMAD) to maximize reginal lung deposition (e.g., bronchial and alveolar areas). o Determination of exposure chamber concentration for maximum deposition in mouse lung. o Characterizing the optimum duration need for the largest antibody deposit while retaining safety efficacy.• Multiple antibodies will be assessed o Mouse anti-PD-1 o Mouse anti-TGFbR2o Human anti -PD-1 o Human anti-TGFbR2 o Combination studiesExample 2.
[0059] In one exemplary method, a formulation containing LBL-006 (human anti-PD- 1) was prepared and delivered to mice.
[0060] Formulation: 10 mg / mL of LBL-006 in 20 mM phosphate buffer, and 100 mM NaCl at a pH of 6.9.
[0061] Devices:Ring mode cartridges:* Initial investigation was performed using 10 mg / mL of albuterol at 28.3 LPM using the NGI and UHPLC for analysisMini-MOUDI impactor 135 (TSI) UHPLC (Thermo Fisher Scientific)
[0062] Testing Details:Chamber: The chamber dimensions are 23x11x17 cm and at a volume of 4.29 L. It has 4 exhaust holes, 3 in a triangle pattern and the 4thin the center. The fourth hole is used to connect to the Mini-MOUDI impactor.Flow rate: The chamber rate was set at 2-2.2 LPM which was delocalized through the 3 exhaust holes.Mice: C57BL / 6, 6 females aged at 98 - 104 days weighing 19 - 21 gramsIncubation time: W-3.1-01 and W3-2.8-3 was for 30 minsW3-2.8-6 was for 45 minsConcentration testing: 500 cc of aerosol was withdrawn at 1 / 3 and 2 / 3 time points of the incubation cycle. Aerosol particles were captured in a 0.22 mm nylon syringe filter.
[0063] Device Programing:Initial spray: 0122-7-W-3.1-01 initial ejection was for 10 seconds continuously.0911-W3-2.8-6 and 0911-W3-2.8-3 initial ejection was for 20 seconds continuously.Duty cycle: 0122-7-W-3.1-01 after initial ejection the device switched to 1 second on and 3 seconds off for 7 mins. Then 1 second on 4 seconds off at the until thelO min mark in which it was switched to 1 second on 5 seconds off for the remainder of the incubation duration.0911-W3-2.8-6 after the initial ejection the device switched to 1 second on and 2 seconds off for 6 mins. Then it was switched to 1 second on 3 seconds off, until 26 mins. Finally, the remainder for the time w as set for 1 second on 4 seconds off.091 1 -W3-2.8-3 after the initial ejection the device switched to 1 second on and 2 seconds off for 10.5 mins. Then it was switched to 1 second on 4 seconds off, for the remainder for the time.
[0064] Mouse Preparations for analysis: Mouse lungs were removed and inflated with 10% formalin buffer and stored in the same buffer.
[0065] Analysis: The mouse lungs are histologically analyzed for location and amount of antibody delivery. Air samples from the chamber are analyzed to determine particle size, amount, distribution, and antibody stability.Example 3.
[0066] Mouse lungs from Example 1 were histologically analyzed (Histology' Study No.: H-22-4053). The purpose of this study was to assess the histopathology of lung tissues collected from mice treated with different particle size of human IgG aerosol. HE-stained glass slides were prepared using standard methodology from formalin fixed mouse tissues and evaluated by an ACVP board certified veterinary' pathologist. In addition, the sections were stained for anti-human IgG (Mouse Anti-Human IgGl Hinge-Alexa Fluor ® 647) to localize the presence of human IgG within lungs. Histopathological evaluation of lungs showed normal to low grade acute inflammatory changes. In four mice, there was minimal, mild, and moderate increase in alveolar macrophages and mild acute inflammation in the alveoli. The lungs of two mice were within normal limits. In general, airw ays and pleura were within normal limits. There was no thrombosis, hemorrhage, necrosis, or fibrosis noted. Immunofluorescent staining showed specific positive signal in animal W2.8-6 B (Group 2. Med-High dose, 45 minutes). In addition, a faint staining was observed in animals W3.1-1 B (Group 1, High dose, 30 minutes) and W2.8-3 B (Group 3, Medium dose, 30 minutes). No specific staining was found in other samples. Chromogen-based IHC staining is highly suggested.
[0067] Study Design: The study design is listed in Table 3 A. Briefly. 6 C57BL / 6 female mice aged 98-104 days were dosed with the Test Article (Human IgG) for 30 or 45 minutes.Mice were sacrificed and lung was collected at necropsy and fixed in formalin for the histopathology and immunohistochemistry’ analysis.Table 3A: Study Design
[0068] Histology Materials and Methods: H&E-stained glass slides were prepared from formalin fixed murine lung tissues according to the standard methodology. The study was assigned a histology number H-22-4053 and the tissue list is presented in Table 3B. This study was conducted in compliance with Testing Facility’ Standard Operating Procedures.Table 3B: Organs Examined
[0069] Evaluation was performed using light microscopy by a board-certified veterinary’ pathologist. Histology’ findings were entered into the StarPath Program. Changes were scored using the industry standard 5-point scoring system as described below (Mann, et all, 2012).
[0070] Histopathologic Scoring System:
[0071] 0= Normal - Tissue considered to be normal under the conditions of the study and considering the age, sex and strain of the animal concerned. Alterations may be present which, under other circumstances, would be considered deviations from normal.
[0072] 1= Minimal - The amount of change barely exceeds that which is considered to be within normal limits.
[0073] 2= Mild - In general, the lesion is easily identified but of limited severity. The lesion probably
[0074] does not produce any functional impairment.
[0075] 3= Moderate - The lesion is prominent but there is significant potential for increased severity. Limited tissue or organ dysfunction is possible.
[0076] 4= Severe - The degree is either as complete as considered possible or great enough in intensity or extent to expect significant tissue or organ dysfunction.
[0077] Immunohistochemistry:
[0078] IHC staining was conducted using an anti-human IgG (Mouse Anti-Human IgGl Hinge-Alexa Fluor ® 647. supplier: Southern Biotech, clone number: 4E3, Cat# 9052-31) at concentration of 5 ug / mL. Diluent was used as negative control. The sections were treated with CAS protein blocking buffer (Life Technologies, Cat# 008120) for 1 hour at room temperature followed by 1 hour incubation with the anti-human IgG antibody. Then, the sections were washed with phosphate buffered saline (PBS) and treated with Vector® TrueVIEW® Autofluorescence Quenching Kit (Vector. Cat# SP-8400-15) to reduce the tissue autofluorescence. DAPI counterstaining was used for visualization of nuclei. The sections were coverslipped and fluorescent images were taken using Olympus VS200 slide scanner. The micrograph are provided in a power point file.
[0079] Histologic Results and Comment:
[0080] The histopathologic findings are presented in Table 3C. Histopathological evaluation of lungs showed normal to low grade acute inflammatory changes. In four mice, there was minimal, mild, and moderate increase in alveolar macrophages and mild acute inflammation in the alveoli. The lungs of two mice w ere within normal limits. In general, airways and pleura were within normal limits. There was no thrombosis, hemorrhage, necrosis, or fibrosis noted. Immunofluorescent staining showed specific positive signal in animal W2.8- 6 B (Group 2, Med-High dose, 45 minutes). In addition, a faint staining was observed in animals W3.1-1 B (Group 1, High dose, 30 minutes) and W2.8-3 B (Group 3, Medium dose, 30 minutes). No specific staining was found in other samples. Chromogen-based IHC staining is highly suggested.Table 3C: StarPath Tables
[0081] Next Steps: The next steps to be performed include:• Use a Chromogen-based IHC staining for increased sensitivity and background noise reduction o Repeat the LBL-006 with optimized conditions: o Increase duration of exposed o Repeat optimum MMAD o Analysis on specific lung regions• Formulation for LBL-015 will be developed o Stability- work oTest aerosol ejection and foam formation• Optimized conditions will be repeated on mice using LBL-015 (see Example 4)Example 4.
[0082] In one exemplary method, a formulation containing LBL-015 (human TGFbR2 / PD-l) is prepared and is delivered to mice.
[0083] Formulation: 10 mg / mL of LBL-015 in 20 mM citrate buffer, 8.8% (w / v) trehalose dihydrate, 0.02% (w / v) polysorbate 80 at a pH of 5.8.
[0084] Devices:Ring mode cartridges:*Initial investigation is performed using 10 mg / mL of albuterol at 28.3 LPM using the NGI and UHPLC for analysisMini-MOUDI impactor 135 (TSI)UHPLC (Thermo Fisher Scientific)
[0085] Testing Details:Chamber: The chamber dimensions are 23x11x17 cm and at a volume of 4.29 L. It has 4 exhaust holes, 3 in a triangle pattern and the 4thin the center. The fourth hole is used to connect to the Mini-MOUDI impactor.Flow rate: The chamber rate is set at 2-2.2 LPM which is delocalized through the 3 exhaust holes.Mice: C57BL / 6, 6 females aged at 98 - 104 days weighing 19 - 21 gramsIncubation time: W-3. 1-01 and W3-2.8-3 is for 30 minsW3-2.8-6 is for 45 minsConcentration testing: 500 cc of aerosol is withdrawn at 1 / 3 and 2 / 3 time points of the incubation cycle. Aerosol particles is captured in a 0.22 mm nylon syringe filter.
[0086] Device Programing:Initial spray: 0122-7-W-3.1-01 initial ejection is for 10 seconds continuously. 0911-W3-2.8-6 and 0911-W3-2.8-3 initial ejection is for 20 seconds continuously.Duty7cycle: 0122-7-W-3.1-01 after initial ejection the device switches to 1 second on and 3 seconds off for 7 mins. Then 1 second on 4 seconds off at the until the 10 min mark in which it is switched to 1 second on 5 seconds off for the remainder of the incubation duration.0911-W3-2.8-6 after the initial ejection the device switches to 1 second on and 2 seconds off for 6 mins. Then it is switched to 1 second on 3 seconds off, until 26 mins. Finally, the remainder for the time is set for 1 second on 4 seconds off.0911-W3-2.8-3 after the initial ejection the device switches to 1 second on and 2 seconds off for 10.5 mins. Then it is switched to 1 second on 4 seconds off, for the remainder for the time.
[0087] Mouse Preparations for analysis: Mouse lungs are removed and inflated with 10% formalin buffer and stored in the same buffer.
[0088] Analysis: The mouse lungs are histologically analyzed for location and amount of antibody delivery. Air samples from the chamber are analyzed to determine particle size, amount, distribution, and antibody stability7.Example 5.
[0089] In an exemplary method, the formulas from the previously Examples are optimized to reduce foam (for example, 0.02% antifoam A) and / or are optimized for stability (for example, changing salt concentrations 10 mM - 400 mM, changing the concentration of trehalose and Tween 80 (polysorbate 80), using Tween 20 (polysorbate 20), and / or changing the pH).
[0090] It will be understood that various modifications may be made to the embodiments of the presently disclosed formulations and treatment methods within the scope of the following claims. Therefore, the above description should not be construed as limiting.
Claims
WHAT IS CLAIMED:
1. A method for treating a precancerous lung condition comprising administering droplets ejected from an electronic droplet deliver}7device directly to a precancerous lesion or dysplasia in a human or animal lung, wherein the droplets include one or more inhalable therapeutic agents are selected from the group consisting of a chemotherapeutic drug, immunotherapeutic agent, monoclonal antibody, check point inhibitor, nucleic acid, gene, antisense oligonucleotide, siRNA, shRNA, and combinations thereof.
2. The method of claim 1 , wherein the one or more inhalable therapeutic agents include two different types of inhalable therapeutic agents.
3. The method of claim 2. further comprising administering a systemic therapeutic agent via at least one of intravenous treatment, injection, and oral ingestion.
4. The method of claim 1, further comprising administering a systemic therapeutic agent via at least one of intravenous treatment, injection, and oral ingestion.
5. The method of claim 1 wherein the one or more inhalable therapeutic agents are selected from the from group consisting of paclitaxel, doxorubicin, gemcitabine, 9- nitrocamptothecin, 5-azacytidine, celecoxib, 5-fluorouracil, cisplatin, and combinations thereof.
6. The method of claim 1 wherein the one or more inhalable therapeutic agents are selected from the from group consisting of IL-2, IL, GM-CSF. CpG-ODN, LPS and combinations thereof.
7. The method of claim 1 wherein the one or more inhalable therapeutic agents are selected from the from group consisting of cetuximab, avidinOX, relatlimab, ipilimumab, dostarlimab, anti-PD-l / TGFbR2 mAb, anti-PD-1 antibody, pembrolizumab, nivolumab, cemiplimab, tislehzumab, atezolizumab, durvalumab, avelumab, and combinations thereof.
8. The method of claim 1 wherein the one or more inhalable therapeutic agents are selected from the from group consisting of PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors. LAG-3 inhibitors, and combinations thereof.
9. The method of claim 1 wherein the one or more inhalable therapeutic agents are selected from the from group consisting of PEI-p53, PEI-IL-12, PEI-PTEN, BC-819, rAAV-ME- 4E-BP1, DNA / Beclinl, PEI-p53, 9 NC-DLPC, and adenoviral -ty pe 5 with human ABCA10 transgene cisplatin, and combinations thereof.
10. The method of claim 1 wherein the one or more inhalable therapeutic agents are selected from the from group consisting of Aktl siRNA, PEI-WT1 RNAi, small hairpin osetopontin, MRP1 and BCL2 ASO, and combinations thereof.
11. A method for treating a cancerous or precancerous lung condition comprising: administering droplets ejected from an electronic droplet delivery' device directly to a precancerous or cancerous treatment site in a lung of a human or animal, wherein the droplets include one or more inhalable therapeutic agents selected from the group consisting of a chemotherapeutic drug, immunotherapeutic agent, monoclonal antibody, check point inhibitor, nucleic acid, gene, antisense oligonucleotide, siRNA, shRNA, and combinations thereof; and administering one or more systemic therapeutic agents to the human or animal via the bloodstream12. The method of claim 11, wherein the systemic therapeutic agent is a chemotherapy drug.
13. The method of claim 12, further comprising administering a systemic therapeutic agent via at least one of intravenous treatment, injection, and oral ingestion.
14. The method of claim 12, wherein the one or more inhalable therapeutic agents are selected from the from group consisting of paclitaxel, doxorubicin, gemcitabine, 9- nitrocamptothecin, 5 -azacy tidine, celecoxib, 5-fluorouracil, cisplatin, and combinations thereof.
15. The method of claim 12, wherein the one or more inhalable therapeutic agents are selected from the from group consisting of IL-2, IL, GM-CSF, CpG-ODN, LPS and combinations thereof.
16. The method of claim 12, wherein the one or more inhalable therapeutic agents are selected from the from group consisting of cetuximab, avidinOX, relatlimab, ipihmumab, dostarlimab, anti-PD-l / TGFbR2 mAb, anti-PD-1 antibody, pembrolizumab, nivolumab, cemiplimab, tislelizumab, atezolizumab, durvalumab, avelumab, and combinations thereof.
17. The method of claim 12. wherein the one or more inhalable therapeutic agents are selected from the from group consisting of PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, LAG-3 inhibitors, and combinations thereof.
18. The method of claim 12, wherein the one or more inhalable therapeutic agents are selected from the from group consisting of PEI-p53. PEI-IL-12. PEI-PTEN, BC-819.rAAV-ME-4E-BPl, DNA / Beclinl, PEI-p53, 9 NC-DLPC, and adenoviral -type 5 with human ABCA10 transgene cisplatin, and combinations thereof.
19. A method for treating a precancerous lung condition comprising: administering a first dose of droplets ejected from an electronic droplet delivery device directly to a precancerous lesion or dysplasia in a human or animal lung, wherein the droplets include one or more inhalable therapeutic agents are selected from the group consisting of a chemotherapeutic drug, immunotherapeutic agent, monoclonal antibody, check point inhibitor, nucleic acid, gene, antisense oligonucleotide, siRNA, shRNA, and combinations thereof; and administering a second dose of droplets ejected from an electronic droplet delivery device directly to a precancerous lesion or dysplasia in a human or animal lung, wherein the droplets include one or more inhalable therapeutic agents are selected from the group consisting of a chemotherapeutic drug, immunotherapeutic agent, monoclonal antibody, check point inhibitor, nucleic acid, gene, antisense oligonucleotide, siRNA, shRNA, and combinations thereof, wherein the one or more inhalable therapeutic agents of the second dose of droplets is not an identical formulation to the first dose of droplets.
20. The method of claim 19, wherein the first dose of droplets includes a combination of two or more different inhalable therapeutic agents and the second dose of droplets includes a combination of two or more different inhalable therapeutic agents.
